Abstract: The present invention relates to the field of oncology and relates to use of (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide or a pharmaceutically acceptable salt thereof or N-(4-(2-fluoro-4-iodophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)cyclopropanesulfonamide or a polymorph thereof, or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions comprising the same, for the preparation of a medicament for the treatment of pancreatic cancer.
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having N-(?-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is CO2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Type:
Grant
Filed:
February 2, 2010
Date of Patent:
January 31, 2012
Assignee:
Ardea Biosciences, Inc.
Inventors:
Jean-Luc Girardet, Yung-hyo Koh, Martha De La Rosa, Zhi Hong, Stanley Lang
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
December 27, 2011
Assignee:
Ardea Biosciences, Inc.
Inventors:
Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Type:
Application
Filed:
June 30, 2011
Publication date:
December 22, 2011
Applicant:
ARDEA BIOSCIENCES INC.
Inventors:
Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Woo-Hong Kim
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Type:
Application
Filed:
June 30, 2011
Publication date:
December 1, 2011
Applicant:
Ardea Biosciences, Inc.
Inventors:
Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
Abstract: This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
September 10, 2010
Date of Patent:
November 22, 2011
Assignee:
Ardea Biosciences, Inc.
Inventors:
Yung-hyo Koh, Zhi Hong, Jean-Michel Vernier, Andreas Maderna
Abstract: Described herein are novel enzyme inhibitors. In some embodiments the enzyme inhibitors are integrase inhibitors, particularly HIV integrase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV integrase as a method of treating or preventing HIV, AIDS or related disorders.
Type:
Application
Filed:
March 28, 2011
Publication date:
November 3, 2011
Applicant:
Ardea Biosciences, Inc.
Inventors:
Huanming CHEN, Jianlin SONG, Jean-Michel VERNIER, Anthony B. PINKERTON, Johnny Y. NAGASAWA
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Type:
Application
Filed:
June 30, 2011
Publication date:
November 3, 2011
Applicant:
Ardea Biosciences, Inc.
Inventors:
Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
Abstract: Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
Abstract: The present invention relates to compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid or pharmaceutically acceptable salts thereof, and to the preparation and use of such compositions, in particular for the treatment of diseases.
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Type:
Application
Filed:
April 6, 2011
Publication date:
August 4, 2011
Applicant:
Ardea Biosciences, Inc.
Inventors:
Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Woo-Hong Kim
Abstract: This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compounds and compositions described herein.
Type:
Application
Filed:
July 28, 2008
Publication date:
March 10, 2011
Applicant:
Ardea Biosciences, Inc.
Inventors:
Jean-Michel Vernier, Colin Edward Rowlings, Jean-Luc Girardet, Stuart Dimock, Barry Quart, Jeffrey N. Miner
Abstract: This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions.
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Type:
Application
Filed:
March 20, 2008
Publication date:
October 21, 2010
Applicant:
Ardea Biosciences, Inc.
Inventors:
Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Woo-Hong Kim
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having N-(?-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is CO2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Type:
Application
Filed:
February 2, 2010
Publication date:
June 3, 2010
Applicant:
Ardea Biosciences, Inc.
Inventors:
Jean-Luc Girardet, Yung-hyo Koh, Martha De La Rosa, Zhi Hong, Stanley Lang
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2. SO3H or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Abstract: A series of S-triazolyl ?-mercaptoacetanilides having N-(?-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is CO2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Type:
Grant
Filed:
August 18, 2008
Date of Patent:
March 23, 2010
Assignee:
Ardea Biosciences, Inc.
Inventors:
Jean-Luc Girardet, Martha de la Rosa, Zhi Hong, Stanley Lang
Abstract: The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.
Type:
Grant
Filed:
July 11, 2008
Date of Patent:
January 26, 2010
Assignee:
Ardea Biosciences, Inc.
Inventors:
Hassan El Abdellaoui, Robert Tam, Huanming Chen, Varaprasad Chamakura, Dinesh Barawkar, Andreas Maderna, Zhi Hong, Stanley Lang
Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.